Sarep­ta touts Duchenne gene ther­a­py up­take, but warns of de­mand flat­ten­ing be­fore po­ten­tial ex­pand­ed la­bel from FDA

Sarep­ta Ther­a­peu­tics an­nounced Wednes­day af­ter­noon that its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py Ele­v­idys pulled in $200 mil­lion in its first half-year on the com­mer­cial mar­ket …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER